MCL1 Inhibitor
Showing 1 - 25 of >10,000
Acute Myeloid Leukaemia Trial in Australia, France, United States (S 64315 (also referred as MIK665) and venetoclax)
Terminated
- Acute Myeloid Leukaemia
- S 64315 (also referred as MIK665) and venetoclax
-
New Haven, Connecticut
- +6 more
Dec 20, 2022
Acute Myeloid Leukaemia Trial in Worldwide (S 64315 (also referred as MIK665) and azacitidine)
Active, not recruiting
- Acute Myeloid Leukaemia
- S 64315 (also referred as MIK665) and azacitidine
-
Houston, Texas
- +6 more
Dec 16, 2022
Multiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), Lymphoma Trial in Worldwide (MIK665)
Completed
- Multiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), Lymphoma
-
Houston, Texas
- +7 more
Jul 27, 2021
Mantle Cell Lymphoma Trial in Duarte (Acalabrutinib, Ublituximab, Umbralisib)
Suspended
- Mantle Cell Lymphoma
- Acalabrutinib
- +2 more
-
Duarte, CaliforniaCity of Hope Medical Center
Jun 7, 2022
Acute Myeloid Leukaemia (AML), Myelodysplastic Syndrome (MDS) Trial in Worldwide (S64315 once a week, S64315 twice a week)
Completed
- Acute Myeloid Leukaemia (AML)
- Myelodysplastic Syndrome (MDS)
- S64315 once a week
- S64315 twice a week
-
New Haven, Connecticut
- +8 more
May 17, 2022
Blastoid Variant Mantle Cell Lymphoma, CCND1 Protein Overexpression, CD20 Positive Trial in Houston (Acalabrutinib, Venetoclax)
Recruiting
- Blastoid Variant Mantle Cell Lymphoma
- +8 more
-
Houston, TexasM D Anderson Cancer Center
Dec 5, 2022
MALT, Nodal Marginal Zone B-cell Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma Trial in Columbus (drug, biological,
Active, not recruiting
- Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue
- +9 more
- BTK inhibitor PCI-32765
- +5 more
-
Columbus, OhioOhio State University Medical Center
Jun 27, 2022
Myopia Trial in Singapore (Myopia Control Lens-1 (MCL1), Myopia Control Lens-2 (MCL2))
Not yet recruiting
- Myopia
- Myopia Control Lens-1 (MCL1)
- Myopia Control Lens-2 (MCL2)
-
Singapore, SingaporeEssilor R&D Centre Singapore
Nov 27, 2023
CCND1 Positive, CCND2 Positive, CCND3 Positive Trial in Houston (drug, other, biological)
Active, not recruiting
- CCND1 Positive
- +6 more
- Ibrutinib
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Jan 11, 2022
Aggressive B-Cell Non-Hodgkin's Lymphoma, Aggressive B-Cell NHL, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Trial
Not yet recruiting
- Aggressive B-Cell Non-Hodgkin's Lymphoma
- +4 more
- (no location specified)
Dec 16, 2022
Acute Myeloid Leukemia, Lymphoma, Mantle-Cell Trial (PEP07)
Not yet recruiting
- Acute Myeloid Leukemia
- Lymphoma, Mantle-Cell
- (no location specified)
Dec 22, 2022
Metastatic Colorectal Cancer Trial (LB-100, Azenosertib)
Not yet recruiting
- Metastatic Colorectal Cancer
- (no location specified)
Oct 31, 2023
Mantle Cell Lymphoma Trial in Beijing (DTRMWXHS-12)
Active, not recruiting
- Mantle Cell Lymphoma
-
Beijing, ChinaPeking University Cancer Hospital
Aug 18, 2021
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Mantle Cell Lymphoma Trial in United States (TGR-1202, Ibrutinib)
Active, not recruiting
- Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- Mantle Cell Lymphoma
-
Monterey, California
- +4 more
Aug 29, 2022
Metastatic Microsatellite-stable Colorectal Cancer Trial (LB-100, Atezolizumab)
Not yet recruiting
- Metastatic Microsatellite-stable Colorectal Cancer
- (no location specified)
Sep 1, 2023
Nasopharyngeal Carcinoma Trial in Shanghai (Anti-EGFR and PD-1 inhibitor arm)
Recruiting
- Nasopharyngeal Carcinoma
- Anti-EGFR and PD-1 inhibitor arm
-
Shanghai, Shanghai, ChinaEye & ENT Hospital of Fudan University
Nov 26, 2023
Advanced Solid Tumor Trial in Beijing (Inosine 0.2g orally 3 times/day, PD-1/PD-L1 inhibitor ,chemo/targeting)
Completed
- Advanced Solid Tumor
- Inosine 0.2g orally 3 times/day
- PD-1/PD-L1 inhibitor ,chemotherapy/targeting
-
Beijing, Beijing, ChinaQin li
Mar 30, 2023
Advanced Solid Tumor, Refractory Tumor Trial in Suzhou (Radiotherapy, PD-1/PD-L1 inhibitor, Granulocyte-macrophage
Recruiting
- Advanced Solid Tumor
- Refractory Tumor
- Radiotherapy
- +4 more
-
Suzhou, ChinaThe Second Affiliated Hospital of SchoowUniversity
Sep 14, 2023
Chemo-Induced Thrombocytopenia Trial (Hetrombopag)
Not yet recruiting
- Chemotherapy-Induced Thrombocytopenia
- (no location specified)
Jul 24, 2023